Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt
Research Funding - Exelixis
Gerald Edelman
Research Funding - Exelixis
Nicholas J. Vogelzang
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis
Harriet M. Kluger
Research Funding - Exelixis
Christopher A. Yasenchak
Research Funding - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Michael S. Gordon
Research Funding - Exelixis
Primo Lara
Research Funding - Exelixis